Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology. The company’s product portfolio comprises MG-001, which is in Phase I clinical trials to treat colon cancer; MG-002 that is in preclinical stage for use in the treatment of pancreatic cancer; and MG-003, which is in preclinical stage for use in the treatment of diabetes mellitus. Its research stage products include MG-004 for treating hair loss and MG-005 for use in the treatment of Crohn's disease. The company was founded in 2016 and is based in Hanam-si, South Korea.
Metrics to compare | 322970 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship322970PeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −4.5x | −0.5x | |
PEG Ratio | 0.00 | −0.09 | 0.00 | |
Price/Book | 0.0x | 2.1x | 2.6x | |
Price / LTM Sales | 0.0x | 19.3x | 3.3x | |
Upside (Analyst Target) | 0.0% | 28.6% | 42.8% | |
Fair Value Upside | Unlock | 0.9% | 6.5% | Unlock |